Skip to content

Benefits of telemedicine in Opioid substitution therapy

Telemedicine-assisted buprenorphine induction versus standard of care: a randomised controlled, non-inferiority trial - NIL

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/10/058173
Enrollment
138
Registered
2023-10-03
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F112- Opioid dependence

Interventions

Intervention1: Standard of care (SoC)for Buprenorphine induction.: The standard of care in Drug deaddiction and treatment centre (DDTC) PGIMER, Chandigarh is recovery oriented Buprenorphine/naloxone(B

Sponsors

Postgraduate Institute of Medical Education and Research Chandigarh, India 160012
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Meeting ICD-11 diagnostic criteria of opioid dependence 2. Presence of responsible adult family member 3. Patient or/and family member having access to a mobile phone 4. Willing for daily telemedicine follow-up for at least three consecutive days

Exclusion criteria

Exclusion criteria: 1. Uncooperative patients/ Unwilling caregivers. 2. Previously diagnosed with a comorbid serious mental illness 3. Presenting with comorbid severe physical illness (e.g. Liver, renal dysfunction)

Design outcomes

Primary

MeasureTime frame
Treatment retention at one week. Treatment retention will be defined by the proportion of participants who follows up at the outpatient clinic at 7 ± 3 days of Buprenorphine-naloxone (BPNX)induction.Timepoint: 01 week

Secondary

MeasureTime frame
Abstinence from illegal opioids at follow-ups and total number of days of abstinence from illegal opioids during the follow-up period: abstinence from illicit opioids (i.e., any other non-prescription opioid use except buprenorphine) will be defined by (a) subjective reporting of 7-day abstinence and (b) negative urine screen for morphine and tramadol at the follow-upsTimepoint: 01 week;opioid craving and withdrawal symptoms - opioid cravings and withdrawal will be assessed by structured and standardized instrumentsTimepoint: 01 week;patient-reported outcomes such as quality of life and satisfaction: these constructs will be assessed by structured and standardized instruments.Timepoint: 01 week;Telehealth satisfaction in the TABI group: by appropriate standardized instruments.Timepoint: 01 week

Countries

India

Contacts

Public ContactHarpreet Singh Dhillon

Postgraduate Institute of Medical Education and Research Chandigarh, India

ghoshabhishek12@gmail.com9815890436

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026